ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Herbal Alternatives for Menopause Symptoms (HALT Study)

This study is ongoing, but not recruiting participants.
Study NCT00169299.   Last updated on September 12, 2005.   Information provided by Group Health Cooperative

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Herbal Alternatives for Menopause Symptoms (HALT Study)
Official Title  Herbal Alternatives for Menopause Symptoms: A Randomized Trial
Brief Summary

Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep. The treatment of choice in the medical community for these symptoms is hormone replacement therapy, which is estrogen and sometimes progestin. Many women also use over-the-counter herbal remedies. However, less is known about how well these products work, or their safety. Few have undergone the kind of rigorous testing required of prescription drugs and little is known about their long-term effectiveness in relieving symptoms.

The purpose of this study is to compare several over-the-counter herbal remedies to hormone replacement therapy. Our primary aim is to look at the effects of these remedies on your self-reported menopausal symptoms. We will also be measuring their effects on other factors known to be affected by hormone replacement therapy: cholesterol, blood sugar, bone density, vaginal cell structure, and blood clotting.

Detailed Description

Hormone replacement therapy (HT: estrogen and progestin) remains the treatment of choice for women with vasomotor symptoms, and long-term HT has been recommended for prevention purposes. The demand for alternatives to HT, and the availability and use of over-the-counter products including dietary phytoestrogen supplements, and naturopathic medicines has grown dramatically. Few of these products have faced the rigors of randomized trials and none have been tested to evaluate their effects on long-term outcomes.

The purpose of this 4-year, randomized controlled trial is to evaluate the efficacy and safety of three alternative approaches utilizing phytoestrogens to treat vasomotor symptoms in peri- and postmenopausal women. The treatments were chosen because of the scientific evidence supporting a possible benefit, the availability of products with adequate quality control, their frequency of use in naturopathic medicine, and our ability to blind participants to the intervention. The 5 proposed treatment arms are: 1) conjugated equine estrogen with or without medroxyprogesterone acetate in women with or without an intact uterus respectively; 2) a single herbal product, black cohosh; 3) a multibotanical preparation; 4) a combination regimen that includes the same multibotanical preparation plus soy diet counseling; and 5) placebo. Our primary aim is to compare the effects of three alternative treatments, HRT and placebo on the frequency and intensity of vasomotor symptoms measured by The Wiklund Menopause Symptom Checklist and a daily Vasomotor Symptom Diary. Our secondary aims are to compare the effects of three alternative treatments, HRT and placebo on: 1) vaginal cytology (vaginal maturation index); 2) serum lipids (total cholesterol, HDL and LDL cholesterol, triglycerides); 3) bone mineral density (hip and spine dual energy x-ray absorptiometry scan); 4) glucose metabolism (insulin, fasting blood glucose); and 5) coagulation factors (fibrinogen, PAI-1).

Our hypotheses are that compared to placebo, the three alternative treatments tested in this proposal will; reduce frequency of hot flashes and night sweats, improve vaginal maturation and decrease vagina atrophy as measured by maturation index, lower total cholesterol and LDL with no effect on HDL, reduce the rate of decline in bone mineral density (BMD), and have no effect on glucose metabolism or clotting factors.

To accomplish our specific aims we will: 1) recruit and randomize approximately peri- and post-women to one of 5 treatment arms for one year; 2) collect measurements of primary and secondary outcomes at baseline, 3, 6, and 12 months; and 3) compare changes in outcomes in the groups taking alternative treatments to those in the HRT and placebo groups.

Study Phase Phase IV
Study Type  Interventional
Study Design  Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary Outcome Measure  Self report daily diary of frequency and intensity of vasomotor symptoms at BL, 3, 6 and 12 months.
Wiklund Menopause Symptom Checklist at BL, 3, 6 and 12 months.
Secondary Outcome Measure  Vaginal cytology (vaginal maturation index)at BL, 3 and 12 months.
Serum lipids (total cholesterol, HDL and LDL cholesterol, triglycerides) at BL, 3, 6, and 12 months.
Bone mineral density (hip and spine dual energy x-ray absorptiometry scan) at BL, 6 and 12 months.
Glucose metabolism (insulin, fasting blood glucose) at BL, 3, 6, and 12 months.
Coagulation factors (fibrinogen, PAI-1) at BL, 3, 6, and 12 months.
Condition  Vasomotor Symptoms Associated With Menopause
Intervention  Drug: Black cohosh
Drug: Multibotanical preparation
Drug: Multibotanical preparation + dietary soy counseling
Drug: Conjugated equine estrogen +/- medroxyprogesterone acetate
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Active, not recruiting
Enrollment  351
Start Date  June 2001
Completion Date September 2004
Eligibility Criteria 

Inclusion Criteria:

  • female
  • age 45 - 55
  • peri- or post-menopausal
  • moderate to severe vasomotor symptoms
  • normal thyroid stimulating hormone
  • proof of normal mammogram within past 2 years

Exclusion Criteria:

  • use of HT or oral contraceptives within past 3 months
  • use of herbs or alternative or complementary medicines for vasomotor symptoms within past 1 month
  • medical history of contraindications to HT
  • bone mineral density greater than 2 standard deviations below age specific mean
  • bilateral oophorectomy
  • current use of tamoxifen, raloxifene, bisphosphonates, cholesterol-lowering medications, prescription blood-thinners, or oral steroids
  • pregnant or planning to become pregnant
  • allergy to soybeans or soy protein
  • unable to swallow pills
  • current participation in another investigational drug trial
  • intention to move out of area in the next 12 months
  • non-compliance with procedures involved in screening and run-in trial
Gender Female
Ages 45 Years to 55 Years
Accepts Healthy Volunteers Yes
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00169299
Organization ID R01 AG017057
Secondary IDs ††
Study Sponsor  Group Health Cooperative
Collaborators †† National Institute on Aging (NIA)
National Center for Complementary and Alternative Medicine (NCCAM)
Investigators 
Principal Investigator:     Katherine M Newton, PhD     Group Health Cooperative, Center for Health Studies    
Information Provided By Group Health Cooperative
Verification Date September 2005
First Received Date  September 12, 2005
Last Updated Date September 12, 2005

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers